Suppr超能文献

乙肝表面抗原阴性的慢性肝病患者中抗-HBc阳性与肝细胞癌的关联:一项荟萃分析。

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis.

作者信息

Coppola Nicola, Onorato Lorenzo, Sagnelli Caterina, Sagnelli Evangelista, Angelillo Italo F

机构信息

Department of Mental Health and Public Medicine, Section of Infectious Diseases Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara" Department of Experimental Medicine, Second University of Naples, Naples, Italy.

出版信息

Medicine (Baltimore). 2016 Jul;95(30):e4311. doi: 10.1097/MD.0000000000004311.

Abstract

A meta-analysis was performed to ascertain to what extent hepatitis B surface antigen (HBsAg)-negative/anti-hepatitis B core (anti-HBc)-positive subjects with chronic liver disease are at a higher risk of developing hepatocellular carcinoma (HCC) than the anti-HBc-negative.All studies included had to fulfill the following characteristics and inclusion criteria: they investigated the relationship between HBsAg-negative/anti-HBc-positive serology and the occurrence of HCC, whether a case-control or cohort study, they provided relative risk (RR) or odds ratios (ORs) and 95% confidence intervals (CIs), were available as a full text written in English, and were published and indexed up to April 2015.Twenty-six original studies met the inclusion criteria, allowing a meta-analysis on 44,553 patients. The risk of HCC among the 9986 anti-HBc-positive subjects was 67% higher than in the 34,567 anti-HBc-negative (95% CI = 1.44-1.95, P < 0.0001). The results were similar when groups of patients with a different stage of liver disease (patients with chronic liver disease, patients with cirrhosis), with different ethnicity (Asian and non-Asian) and etiology (HCV and non-HCV) were considered. The risk of HCC was significantly higher in the 651 anti-HBs/anti-HBc-positive patients (RR = 1.36; 95% CI = 1.17-1.58, P = 0.03) and in the 595 anti-HBs-negative/anti-HBc-positive subjects (RR = 2.15; 95% CI = 1.58-2.92, P < 0.0001) than in the 1242 anti-HBs/anti-HBc negative. However, the RR from 8 studies indicated that the risk of HCC was 35% lower among the anti-HBs/anti-HBc-positive subjects compared to the anti-HBs-negative/anti-HBc-positive (RR = 0.65; 95% CI = 0.52-0.8, P < 0.0001).This meta-analysis shows that in HBsAg-negative subjects with chronic liver disease, anti-HBc positivity is strongly associated with the presence of HCC, an association observed in all subgroups according to the stage of the disease, etiology, and ethnicity.

摘要

进行了一项荟萃分析,以确定慢性肝病患者中乙肝表面抗原(HBsAg)阴性/乙肝核心抗体(抗-HBc)阳性者发生肝细胞癌(HCC)的风险比抗-HBc阴性者高多少。纳入的所有研究必须具备以下特征和纳入标准:研究HBsAg阴性/抗-HBc阳性血清学与HCC发生之间的关系,无论是病例对照研究还是队列研究,提供相对风险(RR)或比值比(OR)以及95%置信区间(CI),以英文全文形式可得,且发表并索引至2015年4月。26项原始研究符合纳入标准,可对44553例患者进行荟萃分析。9986例抗-HBc阳性受试者发生HCC的风险比34567例抗-HBc阴性者高67%(95%CI = 1.44 - 1.95,P < 0.0001)。当考虑不同肝病阶段(慢性肝病患者、肝硬化患者)、不同种族(亚洲人和非亚洲人)以及病因(丙型肝炎病毒感染和非丙型肝炎病毒感染)的患者组时,结果相似。651例抗-HBs/抗-HBc阳性患者(RR = 1.36;95%CI = 1.17 - 1.58,P = 0.03)和595例抗-HBs阴性/抗-HBc阳性受试者(RR = 2.15;95%CI = 1.58 - 2.92,P < 0.0001)发生HCC的风险显著高于1242例抗-HBs/抗-HBc阴性者。然而,8项研究的RR表明,抗-HBs/抗-HBc阳性受试者发生HCC的风险比抗-HBs阴性/抗-HBc阳性者低35%(RR = 0.65;95%CI = 0.52 - 0.8,P < 0.0001)。这项荟萃分析表明,在慢性肝病的HBsAg阴性受试者中,抗-HBc阳性与HCC的存在密切相关,在根据疾病阶段、病因和种族划分的所有亚组中均观察到这种关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f52/5265845/cf45cfdeb653/medi-95-e4311-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验